Quotes 5-day view End-of-day quote Tokyo Stock Exchange
10/16/2020
10/19/2020
10/20/2020
10/21/2020
10/22/2020
Date
1488.5
1497.5
1486.5
1510
1486
Last
4882300
4580900
4040000
4658900
4978000
Volume
+0.61% +0.60% -0.73% +1.58% -1.59% Change
Sales 2021
1 274 B 12 145 M 12 145 M
Net income 2021
204 B 1 947 M 1 947 M
Net cash position 2021
450 B 4 287 M 4 287 M
P/E ratio 2021
13,4x
Yield 2021
2,84%
Sales 2022
1 346 B 12 836 M 12 836 M
Net income 2022
231 B 2 199 M 2 199 M
Net cash position 2022
578 B 5 507 M 5 507 M
P/E ratio 2022
11,8x
Yield 2022
3,12%
Capitalization
2 760 B 26 386 M 26 314 M
EV / Sales 2021
1,81x
EV / Sales 2022
1,62x
Nbr of Employees
15 883
Free-Float
99,2%
Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders.
Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).
Notations Surperformance© of Astellas Pharma Inc.
Trading Rating : Investor Rating :
All news about ASTELLAS PHARMA INC.
News in other languages on ASTELLAS PHARMA INC.
Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 million
Chart ASTELLAS PHARMA INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ASTELLAS PHARMA INC.
Short Term Mid-Term Long Term Trends Bearish Bearish Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
12
Average target price
2 275,00 JPY
Last Close Price
1 486,00 JPY
Spread / Highest target
81,7%
Spread / Average Target
53,1%
Spread / Lowest Target
14,4%
Please enable JavaScript in your browser's settings to use dynamic charts.
United Kingdom
Canada
France
Deutschland
Schweiz (DE)
Report
